bromocriptine has been researched along with Cardiovascular Diseases in 29 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (13.79) | 18.7374 |
| 1990's | 3 (10.34) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 16 (55.17) | 24.3611 |
| 2020's | 6 (20.69) | 2.80 |
| Authors | Studies |
|---|---|
| Adams, J; Agyin, C; Alatrach, M; Cersosimo, E; Chamarthi, B; Chilton, R; Cincotta, AH; Cominos, N; DeFronzo, RA; Ezrokhi, M; Triplitt, C | 1 |
| Basiak, M; Krysiak, R; Okopień, B; Szkróbka, W | 1 |
| Cincotta, AH | 1 |
| Bloomgarden, Z; Cao, M | 1 |
| Davis, S; Siamashvili, M | 1 |
| Cincotta, AH; Ezrokhi, M; Luo, S; Zhang, Y | 1 |
| Goldman, JD | 1 |
| Krysiak, R; Okopień, B; Szkróbka, W | 1 |
| Garg, SK; Michels, AW; Shah, VN | 1 |
| Descamps, P; Jeanneteau, P; Mercier, MB; Parot-Schinkel, E; Sentilhes, L | 1 |
| Krysiak, R; Okopien, B | 1 |
| Blonde, L; Chamarthi, B; Cincotta, AH; Ezrokhi, M; Gaziano, JM; Rutty, D; Scranton, RE; Vinik, A | 1 |
| Gilowski, W; Krysiak, R; Okopien, B; Szkrobka, W | 1 |
| Lamos, EM; Levitt, DL; Munir, KM | 1 |
| Krysiak, R; Okopień, B; Okrzesik, J; Szkrobka, W | 1 |
| Banerjee, SK; Katare, PB | 1 |
| Chamarthi, B; Cincotta, AH; Ezrokhi, M; Rutty, D | 1 |
| Cincotta, AH; Ezrokhi, M; Gaziano, JM; Ma, ZJ; O'Connor, CM; Rutty, D; Scranton, RE | 1 |
| Bell, DS | 2 |
| Blonde, L; Bohannon, N; Cincotta, AH; Gaziano, JM; Scranton, R; Vinik, A | 1 |
| Morris, JG | 1 |
| Herings, RM; Stricker, BH | 1 |
| Iffy, L | 1 |
| Fournié, A; Graille, V; Montastruc, JL | 1 |
| Bohmer, T; Halse, J; Haugen, HN | 1 |
| Busnardo, B; Girelli, ME; Piccolo, M; Rubello, D | 1 |
| Baker, T; Bakht, FR; Kirshon, B; Miller, LG | 1 |
8 review(s) available for bromocriptine and Cardiovascular Diseases
| Article | Year |
|---|---|
Brain Dopamine-Clock Interactions Regulate Cardiometabolic Physiology: Mechanisms of the Observed Cardioprotective Effects of Circadian-Timed Bromocriptine-QR Therapy in Type 2 Diabetes Subjects.
Topics: Animals; Brain; Bromocriptine; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dopamine; Dopamine Agonists; Insulin; Insulin Resistance; Insulin, Regular, Human; Metabolic Syndrome | 2023 |
Late phase completed clinical trials investigating bromocriptine mesylate quick release as treatment of type 2 diabetes mellitus.
Topics: Adult; Blood Glucose; Bromocriptine; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dopamine Agonists; Humans; Hypoglycemic Agents; Receptors, Dopamine D2; Risk Reduction Behavior | 2021 |
Use of non-insulin therapies for type 1 diabetes.
Topics: Allylamine; Animals; Blood Glucose; Bromocriptine; Cardiovascular Diseases; Colesevelam Hydrochloride; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Gastrins; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Islet Amyloid Polypeptide; Leptin; Metformin; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiazolidinediones; United States | 2013 |
A review of dopamine agonist therapy in type 2 diabetes and effects on cardio-metabolic parameters.
Topics: Animals; Biomarkers; Blood Glucose; Bromocriptine; Cabergoline; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Dopamine Agonists; Ergolines; Humans; Hypoglycemic Agents; Risk Factors; Treatment Outcome | 2016 |
Repositioning of Drugs in Cardiometabolic Disorders: Importance and Current Scenario.
Topics: Allopurinol; Aspirin; Bromocriptine; Cardiovascular Diseases; Clonidine; Colesevelam Hydrochloride; Diabetes Mellitus; Drug Discovery; Drug Evaluation, Preclinical; Drug Repositioning; Humans; Metabolic Syndrome; Piperazines; Tadalafil | 2016 |
Why does quick-release bromocriptine decrease cardiac events?
Topics: Bromocriptine; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Oxidative Stress; Postprandial Period | 2011 |
Focusing on cardiovascular disease in type 2 diabetes mellitus: an introduction to bromocriptine QR.
Topics: Blood Glucose; Bromocriptine; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dopamine Agonists; Humans; Hyperglycemia; Risk Assessment | 2012 |
Lethal cardiovascular complications in patients receiving bromocriptine for ablactation.
Topics: Adult; Bromocriptine; Cardiovascular Diseases; Fatal Outcome; Female; Humans; Lactation | 1995 |
7 trial(s) available for bromocriptine and Cardiovascular Diseases
| Article | Year |
|---|---|
Different effects of cabergoline and bromocriptine on metabolic and cardiovascular risk factors in patients with elevated prolactin levels.
Topics: Adult; Blood Glucose; Bromocriptine; Cabergoline; Cardiovascular Diseases; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Insulin Resistance; Insulin-Like Growth Factor I; Lipids; Middle Aged; Prolactin; Risk Factors | 2015 |
Timed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes Mellitus.
Topics: Aged; Blood Glucose; Bromocriptine; Cardiovascular Diseases; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Disease Progression; Dopamine Agonists; Double-Blind Method; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Middle Aged; Treatment Outcome | 2015 |
The Effect of Atorvastatin on Cardiometabolic Risk Factors in Bromocriptine-Treated Premenopausal Women with Isolated Hypercholesterolemia.
Topics: Adult; Atorvastatin; Bromocriptine; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diet; Dopamine Agonists; Exercise; Female; Fibrinogen; Homocysteine; Humans; Hypercholesterolemia; Hyperprolactinemia; Hypoglycemic Agents; Hypolipidemic Agents; Metformin; Middle Aged; Premenopause; Risk Factors; Uric Acid | 2015 |
Impact of bromocriptine-QR therapy on cardiovascular outcomes in type 2 diabetes mellitus subjects on metformin.
Topics: Aged; Blood Glucose; Bromocriptine; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dopamine Agonists; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Male; Metformin; Middle Aged; Risk Factors | 2016 |
Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes.
Topics: Aged; Bromocriptine; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Dopamine Agonists; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Placebos; Risk Factors; Risk Reduction Behavior; Treatment Outcome | 2010 |
Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects.
Topics: Aged; Bromocriptine; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dopamine Agonists; Double-Blind Method; Female; Humans; Intention to Treat Analysis; Male; Middle Aged; Receptors, Dopamine D2; Risk Factors; Treatment Outcome | 2012 |
Bromocriptine treatment in acromegaly: clinical and biochemical effects.
Topics: Acromegaly; Adult; Bromocriptine; Cardiovascular Diseases; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Evaluation; Erythrocyte Volume; Female; Gastrointestinal Diseases; Glucose Tolerance Test; Growth Hormone; Humans; Hydroxyproline; Male; Middle Aged; Time Factors | 1977 |
14 other study(ies) available for bromocriptine and Cardiovascular Diseases
| Article | Year |
|---|---|
Bromocriptine-QR Therapy Reduces Sympathetic Tone and Ameliorates a Pro-Oxidative/Pro-Inflammatory Phenotype in Peripheral Blood Mononuclear Cells and Plasma of Type 2 Diabetes Subjects.
Topics: Bromocriptine; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glycogen Synthase Kinase 3 beta; Humans; Interleukin-18; L-Selectin; Leukocytes, Mononuclear; NF-E2-Related Factor 2; NIMA-Interacting Peptidylprolyl Isomerase; NLR Family, Pyrin Domain-Containing 3 Protein; Normetanephrine; Oxidative Stress; Phenotype; Prolactin; RNA, Messenger; Superoxide Dismutase-1; Sympatholytics; Thiobarbituric Acid Reactive Substances; Toll-Like Receptor 2; Toll-Like Receptor 4 | 2022 |
Impaired Cardiometabolic Effects of Bromocriptine in Men With Early-Onset Androgenic Alopecia.
Topics: Alopecia; Bromocriptine; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, HDL; Fibrinogen; Humans; Insulin Resistance; Male; Prolactin; Risk Factors; Testosterone; Triglycerides; Uric Acid | 2023 |
New insights into the older hypoglycemic agents in type 2 diabetes therapy.
Topics: Acarbose; Blood Glucose; Bromocriptine; Cardiovascular Diseases; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2020 |
Time-of-Day-Dependent Effects of Bromocriptine to Ameliorate Vascular Pathology and Metabolic Syndrome in SHR Rats Held on High Fat Diet.
Topics: Animals; Bromocriptine; Cardiovascular Diseases; Circadian Rhythm; Diet, High-Fat; Hormone Antagonists; Hypertension; Insulin Resistance; Male; Metabolic Syndrome; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley | 2021 |
Antihyperglycemic medications for cardiovascular disease risk reduction.
Topics: Benzhydryl Compounds; Bromocriptine; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glucosides; Humans; Hypoglycemic Agents; Risk Reduction Behavior; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones | 2018 |
Different effects of fenofibrate on cardiometabolic risk factors in young women with and without hyperprolactinemia.
Topics: Adult; Age Factors; Biomarkers; Bromocriptine; Cardiovascular Diseases; Case-Control Studies; Dopamine Agonists; Dyslipidemias; Female; Fenofibrate; Humans; Hyperprolactinemia; Hypolipidemic Agents; Lipids; Middle Aged; Prolactin; Risk Factors; Sex Factors; Time Factors; Treatment Outcome; Young Adult | 2019 |
[Inhibition of lactation: end to the bromocriptin, long life to the carbergolin?].
Topics: Bromocriptine; Cabergoline; Cardiovascular Diseases; Ergolines; Female; France; Hormone Antagonists; Humans; Lactation | 2014 |
The effect of fenofibrate on cardiometabolic risk factors in bromocriptine-treated women with mixed dyslipidemia: A pilot study.
Topics: Adult; Blood Glucose; Bromocriptine; Cardiovascular Diseases; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Humans; Hypolipidemic Agents; Metabolic Diseases; Middle Aged; Pilot Projects; Risk Factors; Treatment Outcome; Young Adult | 2016 |
Inhibition of lactation: risks associated with dopamine agonists.
Topics: Bromocriptine; Cardiovascular Diseases; Dopamine Agonists; Female; France; Humans; Lactation; Nervous System Diseases | 2011 |
The drug treatment of Parkinson's disease.
Topics: Amantadine; Bromocriptine; Cardiovascular Diseases; Chemical Phenomena; Chemistry; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Nausea; Parasympatholytics; Parkinson Disease | 1984 |
Bromocriptine and suppression of postpartum lactation. The incidence of adverse cardiovascular effects in women of child-bearing age.
Topics: Adolescent; Adult; Bromocriptine; Cardiovascular Diseases; Female; Follow-Up Studies; Humans; Lactation; Postpartum Period; Pregnancy; Product Surveillance, Postmarketing; Treatment Outcome | 1995 |
[Bromocriptine, lactation inhibition and drug monitoring].
Topics: Adult; Adverse Drug Reaction Reporting Systems; Bromocriptine; Cardiovascular Diseases; Female; France; Humans; Lactation; Nervous System Diseases | 1994 |
Severe hyperthyroidism due to neoplastic TSH hypersecretion in an old man.
Topics: Bromocriptine; Cardiovascular Diseases; Humans; Hyperthyroidism; Male; Methimazole; Middle Aged; Pituitary Gland; Pituitary Neoplasms; Thyrotropin; Thyroxine; Triiodothyronine | 1989 |
Possible cocaine predisposition to adverse cerebrovascular and cardiovascular sequelae of bromocriptine administered postpartum.
Topics: Adult; Blindness; Bromocriptine; Cardiovascular Diseases; Cerebrovascular Disorders; Cocaine; Female; Headache; Humans; Seizures; Substance-Related Disorders | 1989 |